iBio, Inc.

IBIO · Nasdaq · SIC 2834: Pharmaceutical Preparations
370
SEC Filings

Business Summary

iBio, Inc. is a preclinical stage biotechnology company using Artificial Intelligence (AI) and machine learning (ML) to develop precision antibody therapeutics targeting obesity and cardiometabolic diseases. Key pipeline assets include IBIO-600 (anti-myostatin antibody) and IBIO-610 (Activin E antibody), developed via an AI-enabled epitope steering and antibody optimization platform. The company operates from a San Diego R&D laboratory and anticipates first human clinical trials in late fiscal 2026 or early fiscal 2027.

Next Earnings

Q2 FY2026 — expected 2026-09-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionIBIOdiscussed_in_filing Artificial Intelligence
topic_mentionIBIOdiscussed_in_filing Cybersecurity
topic_mentionIBIOdiscussed_in_filing Trusted Computing
topic_mentionIBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBIOdiscussed_in_filing Regulation
topic_mentionIBIOdiscussed_in_filing Healthcare & Bio
topic_mentionIBIOdiscussed_in_filing Platform & Ecosystem
topic_mentionIBIOdiscussed_in_filing Artificial Intelligence
topic_mentionIBIOdiscussed_in_filing Cybersecurity
topic_mentionIBIOdiscussed_in_filing Trusted Computing
topic_mentionIBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBIOdiscussed_in_filing Regulation
topic_mentionIBIOdiscussed_in_filing Healthcare & Bio
topic_mentionIBIOdiscussed_in_filing Platform & Ecosystem
topic_mentionIBIOdiscussed_in_filing Artificial Intelligence
topic_mentionIBIOdiscussed_in_filing Cybersecurity
topic_mentionIBIOdiscussed_in_filing Trusted Computing
topic_mentionIBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBIOdiscussed_in_filing Regulation
topic_mentionIBIOdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-09-052025-06-300001558370-25-011888EDGAR89K words
2024-09-202024-06-300001420720-24-000038EDGAR—
2023-09-272023-06-300001420720-23-000045EDGAR—
2022-10-112022-06-300001420720-22-000064EDGAR—
2021-09-282021-06-300001558370-21-012819EDGAR—
2020-10-132020-06-300001104659-20-114567EDGAR—
2019-08-262019-06-300001144204-19-041659EDGAR—
2018-09-182018-06-300001144204-18-049866EDGAR—
2017-09-152017-06-300001144204-17-048249EDGAR—
2016-10-132016-06-300001144204-16-127993EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-102025-12-310001420720-26-000004EDGAR37K words
2025-11-122025-09-300001420720-25-000041EDGAR—
2025-05-022025-03-310001420720-25-000025EDGAR—
2025-02-102024-12-310001420720-25-000012EDGAR—
2024-11-122024-09-300001420720-24-000054EDGAR—
2024-05-132024-03-310001420720-24-000020EDGAR—
2024-02-092023-12-310001558370-24-000934EDGAR—
2023-11-142023-09-300001558370-23-019043EDGAR—
2023-05-152023-03-310001558370-23-009707EDGAR—
2023-02-142022-12-310001420720-23-000009EDGAR—
2022-11-142022-09-300001558370-22-017874EDGAR—
2022-05-122022-03-310001420720-22-000024EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-090001420720-26-000006EDGAR5K words
2026-02-270001104659-26-021654EDGAR—
2026-02-100001420720-26-000003EDGAR—
2026-01-120001104659-26-002940EDGAR—
2025-11-210001104659-25-114800EDGAR—
2025-11-170001420720-25-000045EDGAR—
2025-11-120001420720-25-000039EDGAR—
2025-11-040001420720-25-000035EDGAR—
2025-10-300001420720-25-000033EDGAR—
2025-09-050001558370-25-011885EDGAR—

370 total filings indexed. 338 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

obesity-therapeutics cardiometabolic-disease immuno-oncology precision-antibody-biologics

Company Identity

CIK0001420720
TickerIBIO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersSan Diego, California

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 637c9d103d5e5c850d35728baa787d74aea1b7aac13212fda9a7a8723ff31a01
parent: 589feb531aebb45c4053e9513de5681d49bd6694be4dc4d803741117d5a2740c
content hash: 24a251d54307a7b25dcef485156588d431ff307e5ff42970a0ed31f77ee50d43
signed: 2026-04-13T04:45:36.740Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf